Photochemistry and Photobiology · 2007 · 43 citations · 27 references
MedicineOncologyPharmacologyCancer PharmacologyDrug DeliveryPharmacokinetics Of Anticancer AgentsLiposomal FormulationsOncology PharmacologyPharmacokinetics Of Anticancer DrugsPhotodynamic TherapyTumor ImagingCancer Photodynamic TherapyHigh-performance Liquid ChromatographyLiposomal Delivery SystemsLiposomal NanocarriersPhotosensitizer PharmacokineticsTumor SelectivityTumor Tissue TargetingTumor Uptake Kinetics
Meso-tetra(hydroxyphenyl)chlorin (mTHPC) (INN: Temoporfin) is one of the most potent photodynamically active substances in clinical use. Treatment protocols for Temoporfin-mediated photodynamic therapy often rely on drug-light intervals of several days in order for the photosensitizer to accumulate within the target tissue, though tumor selectivity is limited. Here, the mTHPC localization was studied at 2-8 h following systemic administration of a liposomal Temoporfin formulation (0.15 mg kg(-1) b.w.) in HT29 human colon adenocarcinoma in NMRI nu/nu mice. Photosensitizer distribution within tumor and internal organs was investigated by means of high performance liquid chromatography following chemical extraction, as well as in situ fluorescence imaging and point-monitoring fluorescence spectroscopy. For tumor tissue, the Temoporfin concentrations at 4 h (0.16+/-0.024 ng mg(-1)) and 8 h (0.18+/-0.064 ng mg(-1)) were significantly higher than at 2 h (0.08+/-0.026 ng mg(-1)). The average tumor-to-muscle and the tumor-to-skin selectivity were 6.6 and 2, respectively, and did not vary significantly with time after photosensitizer injection. In plasma, the Temoporfin concentration was low (0.07+/-0.07 ng mg(-1)) and showed no significant variation with time. Our results indicate a rapid biodistribution and clearance from the bloodstream. Within the same type of organ, data from both fluorescence methods generally exhibited a significant correlation with the extraction results.
27
Foscan® uptake and tissue distribution in relation to photodynamic efficacy
P. Cramers, Marjan Ruevekamp, Hugo Oppelaar et al. · British Journal of Cancer · 2003 · 130 citations · Full text
Medicine, Oncology, Pharmacology +13